OncoMatch/Clinical Trials/NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Is NCT06312137 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for non small cell lung cancer.
Treatment: Sacituzumab tirumotecan · Pembrolizumab · Cisplatin · Pemetrexed · Gemcitabine · Carboplatin · Paclitaxel · Rescue medication — This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR not indicated as primary therapy
Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy
Required: ALK not indicated as primary therapy
Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy
Required: PD-L1 (CD274) expression (testing required; no eligibility threshold specified)
Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) ... status by central vendor before randomization
Required: TACSTD2 expression (testing required; no eligibility threshold specified)
Tumor tissue sample from surgical resection has been provided for determination of ... trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization
Disease stage
Required: Stage II, IIIA, IIIB
Prior therapy
Must have received: neoadjuvant pembrolizumab and platinum-based doublet chemotherapy — current NSCLC diagnosis
Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy
Cannot have received: neoadjuvant therapy for current NSCLC diagnosis
Has received prior neoadjuvant therapy for their current NSCLC diagnosis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060) · Little Rock, Arkansas
- Highlands Oncology Group-Research Department ( Site 0062) · Springdale, Arkansas
- Beverly Hills Cancer Center ( Site 0070) · Beverly Hills, California
- The Angeles Clinic and Research Institute ( Site 0040) · Los Angeles, California
- The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079) · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06312137 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy for current NSCLC diagnosis disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR not indicated as primary therapy is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK not indicated as primary therapy is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify